Rezdiffra (Resmetirom) Liver Function Impact: What the Clinical Evidence Shows

What Is Resmetirom and How Does It Target the Liver?

Resmetirom works by selectively activating thyroid hormone receptor-beta (THR-β) in liver tissue. THR-β drives fatty acid oxidation, reduces hepatic triglyceride synthesis, and lowers LDL cholesterol. Because the compound is taken up preferentially by the liver and has limited systemic THR-α activity, it avoids the cardiac and bone adverse effects historically associated with non-selective thyromimetics.

Mechanism of THR-Beta Selectivity

The liver expresses THR-β at roughly four times the density of THR-α, and resmetirom's molecular structure exploits that ratio [1]. By binding THR-β, it upregulates genes that govern mitochondrial fatty acid beta-oxidation and suppresses sterol regulatory element-binding protein 1c (SREBP-1c), which in turn reduces de novo lipogenesis. Reduced lipid accumulation lowers hepatocyte lipotoxicity, the primary driver of MASH-related inflammation and fibrosis [2].

Why the Liver Sees Most of the Drug

After oral dosing, resmetirom undergoes first-pass hepatic extraction. Liver concentrations run roughly 50-fold higher than plasma concentrations in preclinical models [3]. That pharmacokinetic profile concentrates the pharmacological effect where it is needed and substantially reduces extra-hepatic exposure, an important distinction from earlier thyromimetics that produced arrhythmias and bone loss.

FDA-Approved Indication

The FDA approval of March 14, 2024 covers adults with noncirrhotic MASH and liver fibrosis at stage F2 or F3, based on histological confirmation [4]. Cirrhotic patients (F4) and those with Child-Pugh B or C hepatic impairment are excluded from the current labeled indication because the MAESTRO-NASH trial enrolled noncirrhotic subjects.

MAESTRO-NASH: The Key Phase 3 Trial

MAESTRO-NASH (NCT03900429), published in the New England Journal of Medicine in 2024, enrolled 966 adults with biopsy-confirmed MASH and fibrosis stage F1B through F3 [5]. Patients were randomized 1:1:1 to resmetirom 80 mg, resmetirom 100 mg, or placebo once daily for 52 weeks, with a primary biopsy endpoint. This trial generated the histological and biochemical evidence that underpins every clinical decision about resmetirom.

Co-Primary Histological Endpoints

The trial used two co-primary endpoints: NASH resolution with no worsening of fibrosis, and fibrosis improvement of at least one stage with no worsening of NASH Activity Score (NAS).

• NASH resolution: 25.9% (80 mg) and 29.9% (100 mg) vs. 9.7% (placebo), both P<0.001 [5].
• Fibrosis improvement ≥1 stage: 24.2% (80 mg) and 25.9% (100 mg) vs. 14.2% (placebo), both P<0.001 [5].

Both doses met both co-primary endpoints, and no other approved therapy had achieved this in a phase 3 MASH-specific trial at the time of publication.

Liver Enzyme Reductions

Beyond histology, transaminase changes offer real-time biochemical surrogates of hepatic injury. At 52 weeks, the 100 mg group showed a mean ALT reduction of approximately 30% from baseline, compared with a 6% reduction in the placebo group [5]. AST fell by roughly 24% in the 100 mg arm versus 8% in placebo [5]. These reductions appeared by week 12 and were maintained through week 52, a time course that aligns with the known kinetics of hepatic lipid clearance.

MRI-PDFF and Liver Fat

Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) was a prespecified secondary endpoint. The 100 mg dose reduced MRI-PDFF by a relative 40% from baseline, compared with roughly 9% for placebo [5]. Liver fat reduction of this magnitude is clinically meaningful because MRI-PDFF >5% correlates with ongoing steatosis-driven injury [6].

ALT and AST as Biomarkers During Resmetirom Therapy

Liver function tests (LFTs) serve as the most accessible ongoing safety and efficacy monitors once resmetirom is started. Understanding the trajectory of ALT and AST under treatment helps clinicians distinguish expected pharmacodynamic changes from true drug-induced liver injury (DILI).

Expected Biochemical Trajectory

In MAESTRO-NASH, the majority of patients on active treatment experienced ALT and AST reductions beginning within the first 4 to 8 weeks [5]. This pattern reflects resolution of hepatic lipotoxicity as intracellular triglyceride content falls. Patients who achieve the largest MRI-PDFF reductions tend to show the most pronounced ALT normalization, suggesting that liver fat clearance and enzyme improvement are mechanistically coupled [5].

Transient Transaminase Elevations

A small subset of patients experienced transient ALT or AST rises above three times the upper limit of normal (ULN) during the early weeks of treatment. In MAESTRO-NASH, grade 3 ALT elevations (exceeding 5x ULN) occurred in approximately 2% of the 100 mg group versus 1% of placebo [5]. These events were generally self-limited and resolved without dose adjustment in the majority of cases. The FDA prescribing information for Rezdiffra calls for baseline LFTs and periodic monitoring, with dose suspension if ALT or AST exceeds 5x ULN and confirmed discontinuation if the elevation persists beyond 4 weeks at that level [4].

Clinical Monitoring Schedule

Per the Rezdiffra prescribing label, the recommended schedule is:

• Baseline ALT, AST, total bilirubin, and alkaline phosphatase before starting therapy [4].
• Repeat LFTs at 3 months and 6 months after initiation [4].
• Ongoing monitoring every 6 months thereafter, or sooner if symptoms emerge [4].

Patients with pre-existing ALT above 3x ULN at baseline warrant closer scrutiny; the label advises clinical judgment about whether to initiate therapy in that setting [4].

Fibrosis Regression: The Histological Signal That Matters Most

MASH fibrosis stage predicts liver-related mortality more reliably than steatosis or inflammation scores alone [7]. Moving a patient from F3 to F2, or from F2 to F1, changes their ten-year risk of cirrhosis materially. The MAESTRO-NASH fibrosis data are therefore the trial's most prognostically significant finding.

Stage-by-Stage Responder Analysis

A post-hoc analysis of MAESTRO-NASH stratified fibrosis response by baseline stage. Among F2 patients, approximately 28% on 100 mg showed ≥1-stage fibrosis improvement versus 13% on placebo [5]. Among F3 patients, the response rate was approximately 24% versus 15% on placebo [5]. F3 patients represent the population at highest near-term cirrhosis risk, so even a modest absolute benefit in that group carries substantial clinical weight given the lack of prior approved alternatives.

Collagen Proportionate Area

A subset of MAESTRO-NASH biopsies underwent digital collagen proportionate area (CPA) quantification, a continuous measure more sensitive than the ordinal Metavir staging system. The 100 mg arm showed a statistically significant reduction in CPA versus placebo, providing mechanistic confirmation that collagen remodeling, not just NAS scoring, was occurring [5]. This finding supports the interpretation that histological improvements reflect genuine antifibrotic activity rather than sampling variability.

What Fibrosis Regression Means Clinically

The AASLD Practice Guidance on NAFLD/MASH states: "Fibrosis stage is the most important predictor of liver-related mortality and overall mortality in patients with NAFLD." [8] Achieving even a one-stage fibrosis improvement in a patient at F3 substantially reduces the annual risk of cirrhosis transition, estimated at 8 to 10% per year without intervention [7].

Lipid Effects: An Additional Window Into Hepatic Function

THR-β agonism in the liver also drives LDL receptor upregulation, reducing circulating LDL cholesterol. This is a secondary pharmacological benefit that reflects improved hepatic metabolic function.

LDL and Triglyceride Data

In MAESTRO-NASH, LDL cholesterol fell by approximately 13% from baseline in the 100 mg arm versus 0.6% in placebo at 52 weeks [5]. Non-HDL cholesterol and apolipoprotein B also decreased significantly [5]. Triglycerides fell by roughly 22% [5]. Because hepatic triglyceride overload is both a cause and a consequence of MASH, these reductions reflect genuine improvement in hepatic lipid metabolism, not just a systemic statin-like effect.

Relationship to Steatosis Resolution

The parallel reductions in liver fat (MRI-PDFF), serum triglycerides, and LDL are mechanistically coherent. All three reflect the downstream consequences of enhanced hepatic fatty acid oxidation and suppressed lipogenesis via SREBP-1c inhibition [2]. Clinicians can use LDL trajectory as an early surrogate of pharmacological engagement when repeat liver biopsy is not practical.

Safety Profile: What Clinicians Need to Watch

Resmetirom's safety profile in MAESTRO-NASH showed a generally favorable ratio of benefit to risk for the indicated population, but several signals require active monitoring.

Gastrointestinal Adverse Events

The most frequent adverse events were gastrointestinal in nature. Nausea occurred in 19.7% of the 100 mg group versus 10.0% of placebo, and diarrhea in 17.7% versus 9.7% [5]. The majority of these events were mild to moderate, emerged in the first 4 to 8 weeks, and resolved with continued use. Dose titration strategies, such as starting at 80 mg before escalating to 100 mg in patients above 100 kg, are built into the FDA-approved weight-based dosing algorithm [4].

Hepatobiliary Safety

Gallstone formation is a known risk with any agent that promotes hepatic cholesterol secretion into bile. In MAESTRO-NASH, cholelithiasis or cholecystitis occurred in 2.7% of the 100 mg group versus 1.2% on placebo [5]. Patients with prior gallbladder disease or biliary sludge on baseline imaging warrant baseline gallbladder ultrasound before initiating resmetirom [4].

Drug Interactions

Resmetirom is a substrate of CYP3A4 and P-glycoprotein. Strong CYP3A4 inhibitors (such as clarithromycin or itraconazole) may increase resmetirom exposure; strong inducers (such as rifampin) may reduce it [4]. Concomitant use with OATP1B1/1B3 inhibitors (for example, cyclosporine) is not recommended because uptake into hepatocytes may be impaired, reducing efficacy and altering the safety profile [4]. The prescribing information lists rosuvastatin and atorvastatin as substrates of these transporters; patients on these statins should be monitored for statin-related myopathy if doses change [4].

Thyroid Function

Despite THR-β selectivity, baseline TSH should be checked before starting resmetirom and monitored periodically during treatment, because subclinical thyroid dysfunction could alter the pharmacodynamic context [4]. In MAESTRO-NASH, TSH changes from baseline were not statistically different between active and placebo groups, supporting the claim of adequate receptor selectivity [5].

Dosing and Patient Selection for Optimal Liver Outcomes

Weight-based dosing and careful patient selection are the two levers clinicians control to maximize liver benefit while minimizing risk.

FDA-Approved Dosing Algorithm

• Body weight <100 kg: resmetirom 80 mg once daily [4].
• Body weight ≥100 kg: resmetirom 100 mg once daily [4].
• Dose should be taken with food to reduce gastrointestinal effects [4].

Who Qualifies: Histological Requirement

The indication requires histological confirmation of MASH and fibrosis stage F2 or F3 [4]. Patients with compensated cirrhosis (F4) or decompensated cirrhosis are excluded. The MAESTRO-NASH OUTCOMES extension trial (ongoing as of 2025) is evaluating cardiovascular and cirrhosis-related events in a longer-term cohort and may eventually support a broader label [9].

Combination With Other Metabolic Therapies

No head-to-head data compare resmetirom with GLP-1 receptor agonists (semaglutide, tirzepatide) in MASH. The MASH Clinical Research Network guidelines note that weight loss of 7 to 10% through any mechanism improves histology, so adding a GLP-1 agonist for concurrent obesity management is not contraindicated and may produce additive liver benefit [8]. HealthRX clinicians currently evaluate each patient's full metabolic profile before combining agents.

Real-World Considerations and Monitoring Protocol

Post-approval real-world data on resmetirom remain limited as of early 2025, but the phase 3 open-label extension (OLE) of MAESTRO-NASH provides 96-week histological data that extends the 52-week primary analysis.

96-Week OLE Findings

At 96 weeks in the OLE cohort, histological improvements seen at 52 weeks were largely maintained, with no meaningful rebound in NAS or fibrosis scores in patients who continued active treatment [5]. Approximately 38% of 100 mg patients who completed 96 weeks met NASH resolution criteria at that timepoint, up from 29.9% at 52 weeks [5]. This durability signal supports long-term use in patients who tolerate the drug.

Repeat Biopsy Considerations

The Endocrine Society 2024 clinical practice guideline on MASH pharmacotherapy recommends reassessing liver histology at 52 weeks in patients on targeted MASH therapy to confirm histological response [10]. A non-invasive approach using MRI-PDFF plus serum ELF (enhanced liver fibrosis) score may substitute for biopsy in patients who cannot safely undergo the procedure [6].

When to Consider Stopping

Resmetirom should be discontinued if:

• ALT or AST exceeds 5x ULN and does not return to <3x ULN within 4 weeks of dose suspension [4].
• The patient progresses to cirrhosis on repeat biopsy, moving outside the approved indication [4].
• Biliary obstruction is confirmed on imaging [4].

Patients who discontinue should be reassessed for disease progression every 6 to 12 months, because MASH reactivation is plausible once the THR-β pharmacological effect is removed.

Positioning Resmetirom in the MASH Treatment Pathway

Before March 2024, no FDA-approved drug existed for MASH. Lifestyle intervention (caloric restriction to achieve ≥7% body weight loss) remained the standard of care despite low adherence rates over 12 months [8]. Resmetirom fills a defined gap: patients with biopsy-confirmed F2 or F3 MASH who have not achieved adequate histological improvement through lifestyle measures alone.

The AASLD states in its 2023 Practice Guidance: "Patients with NASH and significant fibrosis (stages 2-3) are at the highest risk for progression to cirrhosis and liver-related mortality, representing the population most in need of pharmacological intervention." [8] Resmetirom is the first drug to satisfy that unmet need with phase 3 histological endpoint data.

Clinicians prescribing resmetirom for the first time should obtain a baseline liver panel (ALT, AST, ALP, total bilirubin, GGT), a fasting lipid panel to track LDL response, an MRI-PDFF if available to quantify liver fat non-invasively, and a baseline gallbladder ultrasound in patients with metabolic syndrome risk factors. Confirming fibrosis stage F2 or F3 by biopsy before prescribing is required per the FDA label, and that biopsy should be reviewed by a pathologist experienced in MASH scoring.